Zentalis Pharmaceuticals (ZNTL) Assets Average (2020 - 2026)

Zentalis Pharmaceuticals' Assets Average history runs 7 years deep, the most recent figure standing at $271.0 million for Q1 2026.

• On a quarterly basis, Assets Average fell 33.44% year-over-year to $271.0 million in Q1 2026; TTM through Mar 2026 was $271.0 million, a 33.44% decrease from a year earlier, with the FY2025 full-year figure at $359.7 million, down 26.75% from the prior year.
• Assets Average eased to $271.0 million in Q1 2026 per ZNTL's latest filing, from $308.1 million in the prior quarter.
• Across five years, Assets Average topped out at $603.6 million in Q3 2023 and bottomed at $271.0 million in Q1 2026.
• The 5-year median for Assets Average is $486.8 million (2022), against an average of $466.2 million.
• Across the five-year window, Assets Average jumped 58.99% in 2022 and tumbled 33.44% in 2026, its largest moves.
• Year by year, Assets Average stood at $534.3 million in 2022, then advanced by 6.45% to $568.7 million in 2023, then slipped by 22.54% to $440.5 million in 2024, then plunged by 30.05% to $308.1 million in 2025, then declined by 12.04% to $271.0 million in 2026.
• Per Business Quant, the three latest ZNTL Assets Average figures stand at $271.0 million (Q1 2026), $308.1 million (Q4 2025), and $339.5 million (Q3 2025).